Interferon-γ release assay: A simple method for detection of varicella-zoster virus-specific cell-mediated immunity

2009 ◽  
Vol 351 (1-2) ◽  
pp. 71-74 ◽  
Author(s):  
Naruhito Otani ◽  
Koichi Baba ◽  
Toshiomi Okuno
2008 ◽  
Vol 198 (9) ◽  
pp. 1327-1333 ◽  
Author(s):  
Kay Sadaoka ◽  
Shigefumi Okamoto ◽  
Yasuyuki Gomi ◽  
Takeshi Tanimoto ◽  
Toyokazu Ishikawa ◽  
...  

2014 ◽  
Vol 151 (1_suppl) ◽  
pp. P215-P215
Author(s):  
Takahiro Ichihara ◽  
Shin-Ichi Haginomori ◽  
Atsuko Mori ◽  
Atsuko Kanazawa ◽  
Akira Nishikado ◽  
...  

F1000Research ◽  
2015 ◽  
Vol 4 ◽  
pp. 1356 ◽  
Author(s):  
Don Gilden ◽  
Maria Nagel ◽  
Randall Cohrs ◽  
Ravi Mahalingam ◽  
Nicholas Baird

Varicella zoster virus (VZV) is a ubiquitous, exclusively human alphaherpesvirus. Primary infection usually results in varicella (chickenpox), after which VZV becomes latent in ganglionic neurons along the entire neuraxis. As VZV-specific cell-mediated immunity declines in elderly and immunocompromised individuals, VZV reactivates and causes herpes zoster (shingles), frequently complicated by postherpetic neuralgia. VZV reactivation also produces multiple serious neurological and ocular diseases, such as cranial nerve palsies, meningoencephalitis, myelopathy, and VZV vasculopathy, including giant cell arteritis, with or without associated rash. Herein, we review the clinical, laboratory, imaging, and pathological features of neurological complications of VZV reactivation as well as diagnostic tests to verify VZV infection of the nervous system. Updates on the physical state of VZV DNA and viral gene expression in latently infected ganglia, neuronal, and primate models to study varicella pathogenesis and immunity are presented along with innovations in the immunization of elderly individuals to prevent VZV reactivation.


2013 ◽  
Vol 149 (2_suppl) ◽  
pp. P239-P239
Author(s):  
Takahiro Ichihara ◽  
Shin-Ichi Haginomori ◽  
Atsuko Mori ◽  
Atsuko Kanazawa ◽  
Ryo Kawata

Sign in / Sign up

Export Citation Format

Share Document